Department of Pathology, University of Chicago.
Department of Surgery, Section of Urology, University of Chicago, Chicago, IL.
Adv Anat Pathol. 2022 May 1;29(3):117-130. doi: 10.1097/PAP.0000000000000341.
The World Health Organization (WHO) recommends grading of clear cell renal cell carcinoma (RCC) and papillary RCC using the WHO/International Society of Urological Pathology (ISUP) grade, which is primarily based on nuclear features. As the spectrum of RCC continues to evolve, with more recently described subtypes in the past decade, literature evidence on grading these subtypes is limited or not available for some tumor types. Herein, we outline a pragmatic approach to the topic of grading RCC, dividing the contemporarily described RCC subtypes into 7 categories based on the potential clinical applicability of grading as a useful prognostic parameter: (1) RCC subtypes that are reasonably validated and recommended for WHO/ISUP grading; (2) RCC subtypes where WHO/ISUP is not applicable; (3) RCC subtypes where WHO/ISUP grading is potentially clinically useful; (4) inherently aggressive RCC subtypes where histologic classification itself confers an aggressive biologic potential; (5) renal epithelial tumors where WHO/ISUP grading provides potentially misleading prognostic implication; (6) renal epithelial neoplasms where low WHO/ISUP grade features are a prerequisite for accurate histologic classification; and (7) renal epithelial neoplasms with no or limited data on grading or incomplete understanding of the biologic potential. Our aim in outlining this approach is 2-fold: (a) identify the gaps in understanding and application of grading in RCC subtypes so that researchers in the field may perform additional studies on the basis of which the important pathologic function of assignment of grade may be recommended to be performed as a meaningful exercise across a wider spectrum of RCC; and (b) to provide guidance in the interim to surgical pathologists in terms of providing clinically useful grading information in RCC based on currently available clinicopathologic information.
世界卫生组织(WHO)建议使用世界卫生组织/国际泌尿病理学会(ISUP)分级对透明细胞肾细胞癌(RCC)和乳头状 RCC 进行分级,该分级主要基于核特征。随着 RCC 的范围不断扩大,在过去十年中出现了更多最近描述的亚型,因此关于对这些亚型进行分级的文献证据有限或某些肿瘤类型没有相关证据。在此,我们概述了一种实用的 RCC 分级方法,根据分级作为有用的预后参数的潜在临床适用性,将当代描述的 RCC 亚型分为 7 类:(1)经过合理验证并推荐用于 WHO/ISUP 分级的 RCC 亚型;(2)不适用 WHO/ISUP 的 RCC 亚型;(3)WHO/ISUP 分级可能具有临床实用性的 RCC 亚型;(4)固有侵袭性 RCC 亚型,其组织学分类本身赋予侵袭性生物学潜能;(5)WHO/ISUP 分级提供潜在误导性预后意义的肾上皮肿瘤;(6)需要低 WHO/ISUP 分级特征作为准确组织学分类前提的肾上皮肿瘤;以及(7)分级数据有限或缺乏或对生物学潜能了解不完整的肾上皮肿瘤。我们概述这种方法的目的有两个:(a)确定在 RCC 亚型的分级理解和应用方面的差距,以便该领域的研究人员可以在此基础上进行更多的研究,从而推荐将分级的重要病理功能作为一项有意义的工作在更广泛的 RCC 范围内进行;(b)为外科病理学家提供基于当前临床病理信息在 RCC 中提供有临床意义的分级信息的指导。